Evaluating genetic markers in kidney cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit participants diagnosed with renal cell carcinoma to evaluate genetic biomarkers associated with the disease. Initially, 10 patients will be recruited from the urological department at Zealand University Hospital, followed by the analysis of biological materials from an additional 100 patients sourced from the national Biobank. The final phase will involve a gene test on 10 selected patients to further investigate the genetic aspects of kidney cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients who have been diagnosed with kidney cancer.

Exclusion Criteria:

* Patients without signs of malignancy at final histology report.
* Incapacitated patients.

Where it's running

• Zealand University Hospital
  Roskilde, Denmark Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• Side Effects and Resource Navigation Program for Cancer Patients

  This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07646847

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• HC-7366 plus nivolumab with or without ipilimumab for advanced clear-cell kidney cancer (SHARK)

  This trial tests whether adding HC-7366 to nivolumab, with or without ipilimumab, can help control advanced clear-cell kidney cancer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Dallas, Texas and 1 other locations · NCT07401875

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.